Amgen (NASDAQ:AMGN) Price Target Raised to $398.00

Posted by Geri Gentry on Nov 7th, 2026

Amgen (NASDAQ:AMGN – Free Report) had its price target upped by Truist Financial from $380.00 to $398.00 in a research note published on Wednesday morning, MarketBeat Ratings reports. The brokerage currently has a hold rating on the medical research company’s stock.

Several other research firms have also issued reports on AMGN. Cantor Fitzgerald upped their target price on Amgen from $440.00 to $465.00 and gave the company a “neutral” rating in a report on Wednesday. Morgan Stanley cut their price objective on Amgen from $362.00 to $359.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 7th. Sanford C. Bernstein raised their target price on Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research report on Thursday, August 6th. Royal Bank Of Canada lifted their target price on Amgen from $400.00 to $430.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. Finally, UBS Group boosted their price target on shares of Amgen from $430.00 to $470.00 and gave the stock a “buy” rating in a report on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus price target of $420.80.

View Our Latest Research Report on AMGN

Amgen Trading Up 0.0%

AMGN stock traded up $0.14 during mid-day trading on Wednesday, reaching $460.42. The company’s stock had a trading volume of 2,579,312 shares, compared to its average volume of 2,619,150. The company has a market cap of $248.92 billion, a price-to-earnings ratio of 26.71, a price-to-earnings-growth ratio of 3.41 and a beta of 0.43. Amgen has a 12 month low of $312.39 and a 12 month high of $483.99. The business’s 50 day moving average price is $422.43 and its 200 day moving average price is $378.19. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, topping the consensus estimate of $5.79 by $0.66. The company had revenue of $10.37 billion during the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter last year, the firm posted $5.64 EPS. On average, equities research analysts predict that Amgen will post 23.33 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be paid a $2.52 dividend. The ex-dividend date is Friday, November 20th. This represents a $10.08 annualized dividend and a yield of 2.2%. Amgen’s dividend payout ratio is currently 58.47%.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.85% of the company’s stock.

Institutional Trading of Amgen

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quest 10 Wealth Builders Inc. raised its position in Amgen by 220.0% during the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 55 shares in the last quarter. Wellington Altus USA Inc. boosted its holdings in shares of Amgen by 72.3% in the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after purchasing an additional 34 shares in the last quarter. Nvwm LLC increased its position in shares of Amgen by 412.5% during the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 66 shares during the last quarter. PFS Partners LLC increased its position in shares of Amgen by 95.5% during the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 42 shares during the last quarter. Finally, TOWER TRUST & INVESTMENT Co purchased a new position in shares of Amgen during the 3rd quarter valued at about $38,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Amgen reported quarterly earnings and revenue above expectations, with revenue up 8.5% year over year. Its earnings-call discussion also emphasized growth and pipeline momentum, supporting the case for continued expansion. Amgen Earnings Call Highlights Growth, Pipeline Momentum
Positive Sentiment: A large real-world study found Repatha lowered heart-attack risk by 20% versus ezetimibe in patients with heart disease. The findings could strengthen the drug’s clinical and commercial position. Repatha real-world study
Positive Sentiment: Scotiabank reiterated a Buy view and set a $530 price target; UBS also maintains a Buy rating with a $530 target. Separately, ETFs bought a net $79.8 million of AMGN shares in Wednesday’s session. Scotiabank price target ETF holdings
Neutral Sentiment: Analyst opinions remain divided: Leerink Partners and Guggenheim have Hold/neutral ratings, while Scotiabank and UBS are more optimistic. The differing views suggest debate about how much of Amgen’s recent gains are already reflected in its valuation. Leerink Partners rating
Negative Sentiment: Freedom Broker downgraded Amgen to Hold, adding to the cautious analyst commentary and potentially tempering enthusiasm after the recent rally. Freedom Broker downgrade

About Amgen

(Get Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A.